GlassScriptPhysician profile
Alka P Rebentish
NPI 1427012806
$22,677.91
in general payments reported to CMS, 2019-2025
35 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,670 · 2020: $2,519 · 2021: $2,641 · 2022: $2,513 · 2023: $3,131 · 2024: $2,698 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,134 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,134.23 |
| Education | $201.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,736.43 | 2019-2025 | Veklury |
| Viiv Healthcare Company | $3,771.75 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $1,928.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,481.38 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Astellas Pharma US INC | $1,189.61 | 2019-2024 | Cresemba |
| Melinta Therapeutics, LLC | $925.20 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Cipla USA INC. | $898.64 | 2020-2021 | |
| Shionogi INC | $693.30 | 2021-2025 | Fetroja |
| Janssen Biotech, INC. | $638.52 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $605.39 | 2019-2025 | Nuzyra |
| Allergan, INC. | $578.04 | 2019-2020 | |
| Insmed, INC. | $480.19 | 2019-2025 | Arikayce |
| Ferring Pharmaceuticals INC. | $296.98 | 2022-2025 | Rebyota |
| Theratechnologies INC. | $281.70 | 2019-2023 | Trogarzo, Egrifta |
| Philips North America LLC | $244.40 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $240.49 | 2019-2025 | Mytesi |
| Janssen Products, LP | $199.90 | 2020-2021 | |
| Pfizer INC. | $197.56 | 2019-2022 | |
| Amgen INC. | $152.29 | 2019-2020 | |
| Ucb, INC. | $125.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $121.15 | 2024 | Saphnelo |
| Takeda Pharmaceuticals U.S.A., INC. | $120.06 | 2022 | |
| Novo Nordisk INC | $110.65 | 2023 | |
| Celgene Corporation | $110.25 | 2019 | |
| Alexion Pharmaceuticals, INC. | $102.38 | 2019 | |
| Aimmune Therapeutics, INC. | $98.42 | 2024-2025 | Vowst |
| Lilly USA, LLC | $72.77 | 2022 | |
| La Jolla Pharmaceutical Company | $61.77 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $59.51 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $43.32 | 2019 | |
| Dynavax Technologies Corporation | $39.48 | 2019-2023 | Heplisav-B |
| T2 Biosystems, INC. | $21.43 | 2019 | |
| Vyera Pharmaceuticals, LLC | $20.95 | 2020 | |
| Nabriva Therapeutics, Plc | $16.56 | 2021 | |
| Leadiant Biosciences, INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Rebentish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.